Market Overview

Biogen, Orphan Biovitrum Announce Positive ALPROLIX, ELOCTATE Phase 3 Data Across Multiple Hemophilia Populations at ASH

Today Biogen
Idec (NASDAQ: BIIB) and Swedish
Orphan Biovitrum AB (publ) (Sobi) (OTC: SWTUY) announced new results
from Phase 3 studies of their investigational long-lasting recombinant
factor IX and VIII Fc fusion protein candidates for hemophilia B and A,
ALPROLIXTM and ELOCTATETM, including an interim
analysis of pediatric pharmacokinetics (PK) data. These interim data are
the first to demonstrate that ALPROLIX and ELOCTATE have consistently
prolonged half-lives (a measure of the time therapy circulates in the
bloodstream) in children, compared to study participants' prior
therapies. Investigators presented these results, which were consistent
with PK results in adults and adolescents, at the 55th
Annual Meeting of the American Society of Hematology (ASH) in New

See full press release

Posted-In: News Guidance Buybacks Management Global

 

Related Articles (BIIB + SWTUY)

Around the Web, We're Loving...

Get Benzinga's Newsletters